Aleniglipron dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Aleniglipron is a daily GLP-1 pill from Structure Therapeutics. In a 44-week mid-stage study, people lost 16.3 percent more weight than on a dummy pill. Large final-stage studies were set to start in 2026.
Evidence grade for Aleniglipron: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Aleniglipron is a daily GLP-1 pill from Structure Therapeutics. It works like the GLP-1 shots, but you swallow it. There are no food or water rules. It is not approved.
What people take it for
- GLP-1 weight loss without a needle.
- Lower blood sugar.
What studies in people showed
In a 44-week study, the 180 mg dose took off 16.3 percent more weight than a dummy pill. About one person in ten quit the drug. The results were published in 2026. The large final-stage studies were set to start in the third quarter of 2026.
What people report
Reports, not study results
The good
- In the study on this page, a daily pill took off a lot of weight.
The bad
- About one person in ten quit the drug in the study on this page.
Where these come from: Both lines are from the study on this page. We have not collected forum or user reports for this drug yet.
My bottom line
A pill that works like the shots is a big deal for people who hate needles. It is not approved yet. If you want a GLP-1 pill now, ask your doctor about the approved ones.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Aleniglipron has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weightno headcount stated · 1 study
35 of the 36 indexed goals have no study of any kind behind Aleniglipron
No study in people, animals or cells on this page reports a result for these. That does not prove Aleniglipron does nothing for them. It does mean anything you have heard about Aleniglipron and one of these did not come from a study cited here.
Show full evidence
What is Aleniglipron?
Aleniglipron is a daily GLP-1 pill from Structure Therapeutics. In a 44-week mid-stage study, people lost 16.3 percent more weight than on a dummy pill. Large final-stage studies were set to start in 2026.
Aleniglipron is a GLP-1 drug in pill form. It is taken once a day, with no rules about food or water. In a 44-week mid-stage study called ACCESS II, the 180 mg dose took off 16.3 percent more weight than a dummy pill. About 10.4 percent of people stopped taking it. The results were published in Nature Medicine in 2026. Orforglipron, another GLP-1 pill, reported 12.4 percent at 72 weeks. The two studies differ in length and set-up, so the numbers cannot be lined up directly. Large final-stage studies, called ACCOMPLISH, were set to start in the third quarter of 2026.
How does Aleniglipron work?
It is a small molecule that turns on the GLP-1 signal. It copies what the GLP-1 shots do to appetite and blood sugar, in a pill.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Every source here was published in 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 916.0 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Aleniglipron, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026Aleniglipron, an oral small-molecule GLP-1 receptor agonist, in adults with obesity (ACCESS II)
A daily pill took off a large amount of weight. Over 44 weeks, the 180 mg dose took off about 16 percent more body weight than a dummy pill. About one person in ten quit the drug. This is still a mid-stage study, and the larger studies that decide approval have not reported.
16.3% placebo-adjusted weight loss at 44 weeks on 180 mg.
- Study in people2026ACCOMPLISH-1 Phase 3 trial of aleniglipron
This trial is registered and has published nothing. It is the large final-stage program for aleniglipron, set up in 2026 to confirm the weight loss the mid-stage study reported. Trials at this stage are the ones regulators rely on. Until it reads out, the pill's only human evidence is the earlier and smaller study.
Pivotal program registered for 2026.
Common questions
Has Aleniglipron been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Aleniglipron is a daily GLP-1 pill from Structure Therapeutics. In a 44-week mid-stage study, people lost 16.3 percent more weight than on a dummy pill. Large final-stage studies were set to start in 2026.
What is the Aleniglipron dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Aleniglipron FDA-approved?
Investigational; final-stage studies (ACCOMPLISH) starting 2026
How does aleniglipron compare with orforglipron?
Both are GLP-1 pills. Aleniglipron reported more weight loss in a shorter mid-stage study. Orforglipron is already FDA-approved, as Foundayo, with 72-week results from large final-stage studies. No study has tested them side by side.
Can I get aleniglipron?
No. It is experimental and only available inside studies.
Latest reading on Aleniglipron
Blog posts about Aleniglipron, newest first.